Venus MedTech (Hangzhou) Inc. announced interim clinical results from its Target Study evaluating the Cardiovalve transcatheter tricuspid valve replacement system. The study is a prospective, single-arm, multi-center trial involving 125 patients with an average age of 77, conducted across 25 clinical sites in Germany, Spain, Italy, Canada, and the UK. The interim data showed an average device operation time of 58±29 minutes, with the shortest operation recorded at 16 minutes. The company noted that the Cardiovalve Tricuspid Valve Replacement System demonstrated strong efficacy in treating severe tricuspid regurgitation and received positive recognition from global clinical experts. Venus MedTech stated it remains committed to advancing the global clinical development and regulatory registration of its pipeline, including Cardiovalve, but cautioned that there is no guarantee the product will ultimately be successfully marketed.